drugset / Trial / NCT02406989

A Multiple-Ascending Dose Study of MS-553 in Healthy Volunteers

NCT02406989

Phase 1 Completed 32 enrolled MingSight Pharmaceuticals Pty Limited
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, multiple-ascending dose study of MS-553 in healthy volunteers. Endpoints are safety, tolerability, and pharmacokinetics. Subjects are dosed for 14 days.

Timeline

Start
2015-04
Primary completion
2015-08
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject MS-553 Unknown Oral

Indications

No indication recorded.